ATYR Q3 2023 Earnings — aTyr Pharma, Inc. Revenue & Financial Results | Market Cap Arena

ATYRaTyr Pharma, Inc.

$93M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$353,000

Gross Profit

-$640,000-181.3% margin

Operating Income

-$13M-3573.7% margin

Net Income

-$11M-3212.5% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$664,000

Balance Sheet

Total Assets

$125M

Total Liabilities

$27M

Stockholders' Equity

$98M

Cash & Equivalents

$10M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$353,000	$0	—
Gross Profit	-$640,000	-$414,000	-54.6%
Operating Income	-$13M	-$13M	+6.5%
Net Income	-$11M	-$13M	+14.4%